Boston, MA 03/06/2014 (wallstreetpr) – Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR) which is a biopharmaceutical company that specializes in the research and development of RNA interference is currently rated as a “Hold” by TheStreet. The biopharmaceutical company controls a market cap of $412 million with a 30 day share moving average of 288,300.
Its key strengths can be seen in its steady revenue growth that has been ongoing in the recent past accompanied with a solid financial position with reasonable debt levels. Its main weaknesses lie on its low growth rate in net income as well as weak operating cash flow.
Highlights of the Hold ratings
Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR) quarter revenue trails the industry average by 15.7% although it has improved by 0.1% when compared to the same quarter a year ago. Earnings per share continue to decline showing that the company’s revenue growth has not trickled down the company’s bottom line. Tekmira Pharmaceuticals net income has dropped by highs of 77% when compared to the same quarter a year ago.
The solid financial position that Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR) commands is as a result of a zero debt to equity ratio as the company has no debt as of the moment. The company’s turnover ratio is high at 3.02 demonstrating its ability to meet short term cash demands.
The major downside at the moment is Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR)’s declining earnings per share that is slightly lower compared to that of the same quarter a year ago. In the past two years the company has not been able to register a clear trend of positive earnings something that is of a great concern in Wall Street. The company’s change in net income has severely underperformed when compared to the same quarter a year ago, also falling short of the biotechnology industry as well as that of the S&P 500.
Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR) was one of the top gainer in Wednesday trading session moving up by highs of 29.72% to close the day at a high of $24.92.
